Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 14/20 | 0.75 |
| ▸ | MAOA known ✓ | P21397 | 12/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 13/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.75 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.75 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL5070770 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL5075069 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL4332273 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL31133533 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL5070768 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL3406205 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL40651 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL1649712 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL34339 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL13785162 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-113599386-A | Methods for treating a subject having prader-willi syndrome or smith-magenis syndrome | 伊森舍丽斯有限公司 | 2021-11-05 | — | — | CN | claimed |
| CN-107106500-B | Methods for treating a subject having prader-willi syndrome or smith-magenis syndrome | 伊森舍丽斯有限公司 | 2021-07-30 | — | — | CN | claimed |
| EP-3617181-A1 | SYNTHESIS OF TRANS-2-PHENYLCYCLOPROPYLAMINE OR A SALT OR SOLVATE THEREOF | Arevipharma GmbH (DE) | 2020-03-04 | — | — | EP | claimed |
| US-20180280405-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2018-10-04 | — | — | US | claimed |
| US-20180008539-A1 | GASTRORETENTIVE EXTENDED RELEASE SUSPENSION COMPOSITIONS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2018-01-11 | — | — | US | claimed |
| EP-3226839-A1 | GASTRORETENTIVE EXTENDED RELEASE SUSPENSION COMPOSITIONS | Sun Pharmaceutical Industries Ltd (IN) | 2017-10-11 | — | — | EP | claimed |
| WO-2016087952-A1 | GASTRORETENTIVE EXTENDED RELEASE SUSPENSION COMPOSITIONS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-06-09 | — | — | WO | claimed |
| US-20040219186-A1 | Expandable gastric retention device | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY | 2004-11-04 | — | — | US | claimed |
| CN-1543337-A | Expandable gastric retention device | ���ո����ɸߵȽ�����ίԱ�������� | 2004-11-03 | — | — | CN | claimed |
| EP-1416914-A1 | EXPANDABLE GASTRIC RETENTION DEVICE | The State of Oregon acting by and through The State Board of Higher Education on behalf of Oregon State University (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015745-A1 | EXPANDABLE GASTRIC RETENTION DEVICE | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2003-02-27 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-20020035105-A1 | Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain | ENDO PHARMACEUTICALS INC. | 2002-03-21 | — | — | US | claimed |
| EP-0980247-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050044-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-4977145-A | ADMINISTERING ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1990-12-11 | — | — | US | claimed |
| US-3961073-A | 2-PHENYL-CYCLOPROPYLAMINE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280405-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ8 | MAOB 3291/4885MAOA 2984/4885KDM4E 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.